Artivion
AORT
Market cap $1.37B

28.25 USD

-0.49

1.70%

At close Jun 13, 4:00 PM EDT

After hours

28.25

+0.00

0.00%

1 day

-1.70%

5 days

-3.05%

1 month

-2.28%

3 months

20.62%

6 months

-2.35%

Year to date

0.61%

1 year

21.24%

5 years

22.72%

10 years

156.12%

About: Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Employees: 1,600

Healthcare Medical Devices

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

745% more call options, than puts

Call options by funds: $558K | Put options by funds: $66K

300% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 4 (+3) [Q1 2025]

55% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 22

6.62% more ownership

Funds ownership: 90.98% [Q4 2024] → 97.6% (+6.62%) [Q1 2025]

6% more funds holding

Funds holding: 173 [Q4 2024] → 183 (+10) [Q1 2025]

5% less capital invested

Capital invested by funds: $1.09B [Q4 2024] → $1.04B (-$52M) [Q1 2025]

7% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 57

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$32

13%

upside

Avg. target

$33

15%

upside

High target

$33

17%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Daniel Stauder	17%upside $33	Market Outperform Reiterated	6 May 2025
Needham Mike Matson	13%upside $32	Buy Reiterated	6 May 2025

See Analyst Rankings

Financial journalist opinion

Artivion to Participate in Upcoming Investor Conferences

ATLANTA , June 3, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investors conferences. Artivion's management team will present at the upcoming Truist Securities MedTech Conference on Tuesday, June 17, 2025, at the InterContinental Boston Hotel.

Artivion to Participate in Upcoming Investor Conferences

Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

ATLANTA , May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to previously announced, privately negotiated exchange agreements with certain holders (the "Holders") of its 4.250% Convertible Senior Notes due 2025 (the "Notes"). The closing transactions included the closing of an additional, privately negotiated agreement with a separate holder.

Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

ATLANTA , May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning on May 15, 2025 (the "Shares").

Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants John McAulay - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion's First Quarter 2025 Financial Conference Call.

Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Artivion (AORT) Lags Q1 Earnings Estimates

Artivion (AORT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.06 per share a year ago.

Artivion (AORT) Lags Q1 Earnings Estimates

Artivion Reports First Quarter 2025 Financial Results

First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basis Net loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025 Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 2024 30-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference performance goal Submitted the clinical module of the pre-market approval application (PMA) to the FDA for the AMDS Hybrid Prosthesis ATLANTA , May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2025. "I am pleased with our first quarter results as we returned to normal operations following our previously disclosed cybersecurity incident while making substantial progress on our strategic growth initiatives.

Artivion Reports First Quarter 2025 Financial Results

Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA , May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS.

Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results

ATLANTA , April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results

Zacks Investment Research

Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength?

Artivion (AORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength?

Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

ATLANTA , March 4, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m.

Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

See News Rankings

Charts implemented using Lightweight Charts™